降血糖藥物之心血管結果試驗：系統回顧及統合分析

Cardiovascular Outcome Trials of Antidiabetic Agents: A Systematic Review and Meta-analysis

蔡崇煌(Chung-Huang Tsai) ； 張惠雯(Hui-Wen Chang) ； 曾立年(Li-Nien Tseng) ； 顏啟華(Chi-Hua Yen) ； 江韶岳(Shao-Yueh Chiang)

《台灣家庭醫學雜誌》 30卷3期 (2020/09) Pp. 153-168

https://doi.org/10.3966/168232812020093003004

摘要

目的：美國食品藥物管理局建議所有2008年後新上市的降血糖藥物，需進行心血管結果試驗（CVOTs），本研究目的為探討CVOTs，並做一系統回顧及統合分析。方法：以EndNote X9，關鍵詞為“Cardiovascular Outcome(s) Trial(s)＂ OR＂CVOT(s)＂，AND＂Diabetes＂，搜尋2008/1/1至2019/11/30之PubMed medline、Cochrane及Web of Science等資料庫，再由此分別找出降血糖藥物之CVOTs。使用Comprehensive Meta-Analysis 3軟體計算風險比（HR）、95%信賴區間（CI）及權重，並用MS-Excel 2019畫森林圖（forest plot），若誤差線未交叉到1.0無效線，表示達統計學上顯著的差異。結果：共收錄24個研究，其中昇糖素類似胜肽1-受體促效劑（GLP1-RA）可顯著下降12% 3項（3-point, 3-P）主要不良心血管事件（major adverse cardiovascular events, MACE）（HR 0.88, 95% CI 0.82- 0.94），其中SUSTAIN 6（Semaglutide）（0.61, 0.38-0.99）及REWIND（Dulaglutide）（0.76, 0.61-0.95）可顯著下降腦中風風險。鈉－葡萄糖協同轉運蛋白2抑制劑（SGLT2i）可顯著下降11% 3-P MACE（0.89,0.83-0.96），因心衰竭住院（HHF）顯著下降31%（0.69, 0.61-0.79），腎臟疾病進展組合亦有極顯著下降45%（0.55, 0.48-0.64）。二肽基肽酶4抑製劑（Dipeptidyl peptidase 4 inhibitor）為中性結果（0.99, 0.94-1.05），其中CARMELINA（Linagliptin）發現可顯著減少白蛋白尿的進展（0.86, 0.78-0.95），但SAVOR TIMI53（Saxagliptin）因心衰竭住院顯著上昇了27%（1.27, 1.07-1.51）。結論：SGLT2i及GLP1-RA可下降3-P MACE，再者SGLT2i對心衰竭及腎臟亦有保護作用，部份GLP1-RA發現可下降腦中風風險，因此歐美及國內目前對第2型糖尿病治療方針有全新的改變。

關鍵字

心血管結果試驗 ； 主要不良心血管事件 ； 腦中風

並列摘要

Purpose: The US Food and Drug Administration recommends that cardiovascular outcome trials (CVOTs) should be conducted for all new antidiabetic drugs introduced into the market after 2008. The study thus initiated a systematic review and meta-analysis of the CVOTS of antidiabetic agents. Methods: We searched PubMed, Cochrane and Web of Science in EndNote X9 for trial results published from January 1, 2008 to November 30, 2019, using the keywords: ＂Cardiovascular Outcome(s) Trial(s)＂ OR ＂CVOT(s)＂ AND ＂Diabetes＂ to identify the CVOTs of antidiabetic drugs separately. Comprehensive Meta-Analysis 3 was used to calculate the hazard ratios (HR) with 95% CI and weights, and the forest plots were drawn with MS-Excel 2019 with VBA. Significant difference was indicated if the error bars did not cross the no-effect line 1.0. Results: A total of 24 CVOTs were cited. Overall, Glucagon-like peptide 1-receptor agonist (GLP1-RA) was able to significantly reduce 12% 3-point major adverse cardiovascular events (3-P MACE) (HR 0.88, 0.82- 0.94), while SUSTAIN 6 (0.61, 0.38-0.99) and REWIND (Dulaglutide) (0.76, 0.61-0.95) were found to significantly reduce stroke. SGLT2i was able to significantly reduce 3-P MACE by 11% (HR 0.89, 95% CI 0.83-0.96), hospitalization for heart failure (HHF) by 31% (HR 0.69, 95% CI 0.61-0.79), and renal composite by 45% (0.55, 0.48-0.64). Dipeptidyl peptidase 4 inhibitors showed neutral result (0.99, 0.94-1.05); CARMELINA (Linagliptin) could significantly reduce albuminuria progression (0.86, 0.78-0.95). SAVOR TIMI 53 (Saxagliptin), however, appeared to increase HHF by 27% (1.27, 1.07-1.51). Conclusion: In addition to their ability to reduce 3-P MACE, SGLT2i also reports protective effects on HHF and kidneys and GLP1-RA can reduce the risk of stroke, thus facilitating recent changes in type 2 diabetes treatment in Europe, America and Taiwan.

並列關鍵字

CVOTs ； MACE ； stroke

參考文獻

Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al: Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-41.

Di Angelantonio E, Kaptoge S, Wormser D, et al: Association of cardiometabolic multimorbidity with mortality. JAMA 2015; 314: 52-60.

Gerstein HC, Miller ME, Byington RP, et al: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.

Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.

Nissen SE, Wolski K: Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170: 1191-201.